Key Considerations Related to Medical Device, Pharmaceutical, and Biotech Arrangements

With the increased scrutiny on kickbacks regarding medical device, pharmaceutical, and biotech arrangements, there has been an uptick in enforcement activity specific to the use of physicians, advanced practice providers, and other health care providers who consult, speak, serve as advisory board members, or otherwise lend their expertise. Tynan Kugler, Principal, PYA, Mara Smith Kouba, Counsel, Bristol Myers Squibb, and Jonathan Porter, Partner, Husch Blackwell LLP, discuss key regulatory and compliance considerations associated with recent medical device, pharmaceutical, and other biotech settlements (including the Janssen case) and how life sciences companies can navigate the current enforcement environment while engaging physicians and other providers. Tynan, Mara, and Jonathan spoke about this topic at AHLA’s 2024 Annual Meeting in Washington, DC. From AHLA’s Fraud and Abuse and Life Sciences Practice Groups.Tynan, Mara, and Jonathan recently authored an AHLA article on a related case,  Biohaven Pharmaceutical Holding Company Ltd. or Biohaven.Learn more about AHLA's 2025 Annual Meeting in San Diego, CA here.Essential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.

There are no comments yet.

Please log in to write the first comment.